Quantum Group announces results from unbuzzd trial
Quantum BioPharma announced that it has completed a double-blind, randomized, placebo-controlled crossover design clinical trial of its dietary ...
The Hamilton Spectator18d
Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial
placebo-controlled crossover design clinical trial (NCT06505239) of its dietary supplement product unbuzzd™, investigating its effects on alcohol intoxication and alcohol metabolism. TORONTO, Feb. 04, ...
Toronto Star18d
Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial
placebo-controlled crossover design clinical trial (NCT06505239) of its dietary supplement product unbuzzd™, investigating its effects on alcohol intoxication and alcohol metabolism. TORONTO ...
Nasdaq17d
Quantum BioPharma Ltd. Announces Positive Results from Clinical Trial of unbuzzd™ Dietary Supplement for Alcohol Intoxication Relief
placebo-controlled crossover design clinical trial (NCT06505239) of its dietary supplement product unbuzzd™, investigating its effects on alcohol intoxication and alcohol metabolism. Results of ...
Quantum Biopharma (QNTM) Generating A Significant Buzz with Shares Up 230% YTD
Biopharmaceutical company Quantum BioPharma (QNTM) has seen its stock rocket up roughly 230% in the past month. The company ...